Why the study?
Due to the rare incidence of transthyretin amyloidosis cardiomyopathy in Poland, patients face challenges in diagnosis and treatment.
This position statement provides comprehensive recommendations for the diagnosis and management of transthyretin amyloidosis cardiomyopathy in Poland, emphasizing early noninvasive diagnosis and access to tafamidis.
Answers are grounded in this paper and cite their sources.
Standardizes ATTR-CM care in Poland via early noninvasive diagnosis and tafamidis access; extends European consensus with national algorithms.
Considering the rare incidence of transthyretin amyloidosis cardiomyopathy (ATTR-CM) in Poland, patients encounter difficulties at the stages of diagnosis and treatment. For successful diagnosis, it is vital to raise the suspicion of ATTR-CM, that is, to identify typical clinical scenarios such as heart failure with preserved ejection fraction or the red flags of amyloidosis. In most cases, it is possible to establish the diagnosis on the basis of noninvasive tests. This article presents the recommended diagnostic algorithms including laboratory workup, imaging tests (in particular, isotope scanning), and genetic tests. Since ATTR-CM should be differentiated from light chain amyloidosis, we also discuss aspects related to hematological manifestations and invasive diagnosis. We describe neurological signs and symptoms in patients with amyloidosis and present therapeutic options, including the causative treatment of ATTR-CM with the only currently approved drug, tafamidis. We also discuss drugs that are being assessed in ongoing clinical trials. We outline differences in the symptomatic treatment of heart failure in ATTR-CM and recommendations for nonpharmacological treatment and monitoring of the disease. Finally, we underline the need for providing access to the causative treatment with tafamidis as part of a drug program, as in other rare diseases, so that patients with ATTR-CM can be treated according to the European Society of Cardiology guidelines on heart failure and cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Grzybowski et al. (2023) conducted a review in Transthyretin amyloidosis cardiomyopathy (ATTR-CM). The Polish Cardiac Society position statement provides comprehensive diagnostic algorithms and therapeutic recommendations for the management of transthyretin amyloidosis cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: